Education
About Us
Working with TipRanks
Follow Us
Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
GALT Stock Chart & Stats
$5.71
-$0.06(-5.00%)
At close: 4:00 PM EST
$5.71
-$0.06(-5.00%)
Day’s Range― - ―
52-Week Range$1.11 - $7.13
Previous CloseN/A
Volume135.57K
Average Volume (3M)341.94K
Market Cap
$196.02M
Enterprise Value$242.83M
Total Cash (Recent Filing)$11.53M
Total Debt (Recent Filing)$122.31M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 26, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding64,479,210
10 Day Avg. Volume287,288
30 Day Avg. Volume341,945
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)-0.78
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.04K
Enterprise Value/Ebitda-8.05
Forecast
1Y Price Target
$11.00Price Target Upside92.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker ValidationRecent biomarker data validate the drug's biological activity and strengthen confidence in the underlying therapeutic hypothesis, de-risking further clinical work.
Clinical Efficacy SignalsEvidence of reduced incidence of new esophageal varices and lower portal hypertension indicates potential disease-modifying benefit that could enhance regulatory and commercial prospects.
FinancingA new unsecured $10 million convertible line of credit provides incremental capital and reduces immediate funding pressure for ongoing development.
Bears Say
Clinical Timeline UncertaintyPerceived delays from additional regulatory interactions have created concern about extended clinical timelines, which can weigh on share performance.
Investor Sentiment And VolatilityNegative market reaction to headlines about timeline risk may increase share price volatility and make capital access more challenging.
Partnering RiskPerceptions of regulatory uncertainty could deter potential partners and delay licensing discussions, limiting near-term strategic options.
Galectin Therapeutics News
GALT FAQ
What was Galectin Therapeutics Inc’s price range in the past 12 months?
Galectin Therapeutics Inc lowest stock price was $1.11 and its highest was $7.13 in the past 12 months.
What is Galectin Therapeutics Inc’s market cap?
Galectin Therapeutics Inc’s market cap is $196.02M.
When is Galectin Therapeutics Inc’s upcoming earnings report date?
Galectin Therapeutics Inc’s upcoming earnings report date is Mar 26, 2026 which is in 65 days.
How were Galectin Therapeutics Inc’s earnings last quarter?
Galectin Therapeutics Inc released its earnings results on Nov 14, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.02.
Is Galectin Therapeutics Inc overvalued?
According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Undervalued.
Does Galectin Therapeutics Inc pay dividends?
Galectin Therapeutics Inc does not currently pay dividends.
What is Galectin Therapeutics Inc’s EPS estimate?
Galectin Therapeutics Inc’s EPS estimate is -0.1.
How many shares outstanding does Galectin Therapeutics Inc have?
Galectin Therapeutics Inc has 64,479,210 shares outstanding.
What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?
Galectin Therapeutics Inc reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -0.362%.
Which hedge fund is a major shareholder of Galectin Therapeutics Inc?
Currently, no hedge funds are holding shares in GALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (92.64% Upside)
$11.00 (92.64% Upside)
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.58%
Trailing 12-Months
Company Description
Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biotechnology company focused on developing innovative therapies to improve the lives of patients with chronic liver diseases and cancer. The company operates in the biotechnology and pharmaceutical sectors, with a core emphasis on discovering and developing drugs targeting galectin proteins, which are critical in numerous disease processes. Galectin Therapeutics aims to leverage its proprietary technology to create novel treatments, primarily targeting fibrosis and cancer.
GALT Stock 12 Month Forecast
Average Price Target
$11.00
▲(92.64% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
28.07% Insiders
3.86% Mutual Funds
0.19% Other Institutional Investors
64.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---